Research
Hormonal
Perioperative semaglutide use is associated with increased residual gastric content (RGC) in patients undergoing elective esophagogastroduodenoscopy.
Clinicians should consider the timing of semaglutide administration in relation to elective procedures to mitigate RGC risk.
StrongSupportsmedium confidence
Perioperative semaglutide use is associated with increased residual gastric content (RGC) in patients undergoing elective esophagogastroduodenoscopy.
Why this rating
Based on a retrospective study with a large sample size.
Source
Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study
Leonardo Barbosa Santos et al. · Journal of Clinical Anesthesia · 2024
DOI 10.1016/j.jclinane.2024.111668
cohort · n=1094Cited 35×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →